NASDAQ:EDSA - Edesa Biotech Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.00
  • Forecasted Upside: 676.70 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.06
▲ +0.03 (1.48%)

This chart shows the closing price for EDSA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Edesa Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EDSA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EDSA

Analyst Price Target is $16.00
▲ +676.70% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Edesa Biotech in the last 3 months. The average price target is $16.00, with a high forecast of $16.00 and a low forecast of $16.00. The average price target represents a 676.70% upside from the last price of $2.06.

This chart shows the closing price for EDSA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Edesa Biotech.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/20/2021HC WainwrightInitiated CoverageBuy$16.00Low
3/30/2020Brookline Capital ManagementInitiated CoverageBuy$10.00High
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/14/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/13/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/15/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/14/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
6/13/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/13/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/12/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Edesa Biotech logo
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Read More

Today's Range

Now: $2.06
Low: $1.95
High: $2.11

50 Day Range

MA: $1.77
Low: $1.47
High: $2.33

52 Week Range

Now: $2.06
Low: $1.30
High: $12.00

Volume

44,120 shs

Average Volume

76,475 shs

Market Capitalization

$31.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Edesa Biotech?

The following Wall Street sell-side analysts have issued stock ratings on Edesa Biotech in the last twelve months: HC Wainwright.
View the latest analyst ratings for EDSA.

What is the current price target for Edesa Biotech?

1 Wall Street analysts have set twelve-month price targets for Edesa Biotech in the last year. Their average twelve-month price target is $16.00, suggesting a possible upside of 692.1%. HC Wainwright has the highest price target set, predicting EDSA will reach $16.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $16.00 for Edesa Biotech in the next year.
View the latest price targets for EDSA.

What is the current consensus analyst rating for Edesa Biotech?

Edesa Biotech currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EDSA will outperform the market and that investors should add to their positions of Edesa Biotech.
View the latest ratings for EDSA.

What other companies compete with Edesa Biotech?

How do I contact Edesa Biotech's investor relations team?

Edesa Biotech's physical mailing address is 100 SPY COURT, MARKHAM A6, L3R 5H6. The company's listed phone number is (289) 800-9600 and its investor relations email address is [email protected] The official website for Edesa Biotech is www.edesabiotech.com. Learn More about contacing Edesa Biotech investor relations.